Importantly, JHU083 treatment reduces immunosuppressive cell populations in murine models, including monocyte and granulocyte-derived suppressive cells, regulatory T cells, and pro-tumor CD4 + Th17 cells [185]
Jeon S-M, Shin E-A
and decision to submit the manuscript for publication
Potential side effects may include injection-site redness, swelling, bruising, itching, tenderness, small lumps, headache, fatigue, nausea, appetite changes, abdominal discomfort, stool changes, dizziness, altered sleep, mood changes, or feeling off. Allergic or immune reactions are also possible, and the FDA has specifically raised concerns about immunogenicity and peptide-related impurities in compounded BPC-157